Startup
A digital health companion to predict infant asthma risk and provide parent-friendly guidance and clinician insights.
Every investor coverage indicates participated in a round Respiradigm raised.
| Investor | Rounds | Invested |
|---|---|---|
| Curtin University | Accelerator | - |
| Western Australian government | Accelerator | - |
Companies Respiradigm acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Respiradigm. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Curtin University has picked 13 startups for the 2026 intake of its free Accelerate program, which this year spans health, safety, education, beauty and robotics ventures.
WA's New Industries Fund is backing 34 home-grown ventures with over $643,000 in Innovation Booster Grants, most receiving up to $20,000 for commercialisation support, with four funded via a life sciences stream.